Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thonzylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.75 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.75 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.75 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.75 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.75 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.75 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.75 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.75 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.75 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.75 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.75 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.75 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.75 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.65 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.65 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.65 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thonzylamine SCHEMBL121996 | 0.98 | LMNA (0.97) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Thonzylamine SCHEMBL1650305 | 0.97 | LMNA (0.94) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL28086659 | 0.89 | LMNA (0.95) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL4891045 | 0.88 | LMNA (0.97) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL28298127 | 0.87 | LMNA (0.77) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL4075657 | 0.87 | LMNA (0.90) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL17817354 | 0.86 | LMNA (0.76) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL29444024 | 0.86 | LMNA (1.00) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL19114 | 0.86 | LMNA (1.00) | LMNAMAPTTSHRALDH1A1CYP1A2 | |
| Pyrilamine SCHEMBL22118219 | 0.85 | LMNA (0.97) | LMNAMAPTTSHRALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189227-A1 | EASY CHEW FORMULATIONS | HALEON US HOLDINGS LLC | 2024-06-13 | — | — | US | claimed |
| EP-4333895-A1 | EASY CHEW FORMULATIONS | Haleon US IP LLC (US) | 2024-03-13 | — | — | EP | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022235989-A1 | EASY CHEW FORMULATIONS | GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (US) | 2022-11-10 | — | — | WO | claimed |
| WO-2019135123-A1 | LIQUID DOSAGE FORM FOR TOPICAL APPLICATION | NAL PHARMACEUTICAL GROUP LIMITED (CN) | 2019-07-11 | — | — | WO | claimed |
| WO-2019135125-A1 | SEMI-SOLID DOSAGE FORM FOR TOPICAL APPLICATION | NAL PHARMACEUTICAL GROUP LIMITED (CN) | 2019-07-11 | — | — | WO | claimed |
| CN-107441496-A | Oral dosage form | 安能泰制药有限公司 | 2017-12-08 | — | — | CN | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-9579295-B2 | Dosage form for insertion into the mouth | NAL PHARMACEUTICAL GROUP LIMITED (HK) | 2017-02-28 | — | — | US | claimed |
| US-20170020873-A1 | PHARMACEUTICAL COMPOSITIONS | GM PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | claimed |
| US-20100099650-A1 | NASAL SPRAY COMPOSITION AND METHOD FOR TREATING RHINITIS, SINUSITIS OR BOTH | KNAUER KENT A | 2010-04-22 | — | — | US | claimed |
| WO-2008070264-A2 | NASAL SPRAY COMPOSITION AND METHOD FOR TREATING RHINITIS, SINUSITIS OR BOTH | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | claimed |
| CN-101048164-A | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis | YOO SEO HONG (US) | 2007-10-03 | — | — | CN | claimed |
| EP-1814558-A2 | METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS | Yoo, Seo Hong (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060142241-A1 | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis | YOO SEO H | 2006-06-29 | — | — | US | claimed |
| WO-2006050165-A2 | METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS | YOO SEO HONG (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5948414-A | DECONGESTANT, ANTIHISTAMINE, NATURAL OIL OR EXTRACT, NONIONIC EMULSIFIER, TRITERPENE SAPONIN ADJUVANT, WATER | NOUVEAU TECHNOLOGIES, INC. (US) | 1999-09-07 | — | — | US | claimed |